Comment: Zolpidem: Distinct from Triazolam?

Lobo BL Greene WL . Zolpidem: distinct from triazolam?. Ann Pharmacother 1997; 31: 625–32.

Pagot R Cramer P L'Heritier C Coquelin JP Attali P . Comparison of the efficacy and tolerability of zolpidem 20 mg and triazolam 0.5 mg in anxious or depressed insomniac patients. Curr Ther Res 1993; 53: 88–97.

Ochs R Fillingam J Cutter N Leppik I Lucas E Cohn M . The effect of zolpidem in elderly patients with chronic insomnia (abstract). J Sleep Res 1992; 1 (suppl 1): 164.

Lund R Ruther E Wober W . Hippius H. Effects of zolpidem (10 and 20 mg), lormetazepam, triazolam, and placebo on night sleep and residual effects during the day. In: Sauvanet JP Langer SZ Morselli PL , eds. Imidazopyridines in sleep disorders: a novel experimental and therapeutic approach. New York: Raven Press, 1988: 193–203.

Rosenberg J Ahlstrom F . Randomized, double-blind trial of zolpidem 10 mg versus triazolam 0.25 mg for treatment of insomnia in general practice. Scand J Prim Health Care 1994; 12: 88–92.

Wesensten NJ Balkin TJ Belenky GL . Effects of daytime administration of zolpidem and triazolam on performance. Aviat Space Environ Med 1996; 67: 115–20.

Wesensten NJ Balkin TJ Belenky GL . Effects of daytime administration of zolpidem versus triazolam on memory. Eur J Clin Pharmacol 1995; 48: 115–22.

Balkin TJ Odonnell VM Wesensten N McCann U Belenky G . Comparison of the daytime sleep and performance effects of zolpidem versus triazolam. Psychopharmacology 1992; 107: 83–8.

Morselli PL Larribaud J Guillet P Thiercilin JF Barthelet G Grilliat JP . Daytime residual effects of zolpidem: a review of available data. In: Sauvanet JP Langer SZ Morselli PL , eds. Imidazopyridines in sleep disorders: a novel experimental and therapeutic approach. New York: Raven Press, 1988: 183–91.

Gengo FM Cwudzinski DM Manning C . Residual daytime effects of zolpidem, temazepam, and doxylamine in healthy volunteers (abstract). Presented at the 9th Annual Meeting of the Association of Professional Sleep Societies, Nashville, TN, May 30–June 4, 1995: 80.

Gengo FM Gabos C Straley C Manning C . The pharmacodynamics of ethanol: effects on performance and judgment. J Clin Pharmacol 1990; 30: 748–54.

Bergougnan L Hippius H Rüther E Lund R Kreilinger M Speiert A . Study on polysomnographic and daytime residual effects after single doses of zolpidem, triazolam, lormetazepam, and placebo in healthy volunteers (abstract). J Sleep Res 1992; 1 (suppl): 21.

Monti JM Attali P Monti D Zipfel A de la Giclais B Morselli PL . Zolpidem and rebound insomnia — a double-blind, controlled polysomnographic study in chronic insomniac patients. Pharmacopsychiatry 1994; 27: 166–75.

Monti JM Monti D Attali P . Comparative hypnotic and withdrawal effects of zolpidem, triazolam, and placebo in insomniac patients (abstract). J Sleep Res 1992; 1 (suppl): 153.

Wesensten NJ Balkin TJ Davis HQ Belenky GL . Reversal of triazolam- and zolpidem-induced memory impairment by flumazenil. Psychopharmacology 1996; 121: 242–9.

Silvestri R Ferrillo F Murri L Massetani R DiPerri R Rosadini G . Rebound insomnia after abrupt discontinuation of hypnotic treatment: double-blind randomised comparison of zolpidem versus triazolam. Hum Psychopharmacol 1996; 11: 225–33.

Roger M Attali P Coquelin JP . Multicenter, double-blind, controlled comparison of zolpidem and triazolam in elderly patients with insomnia. Clin Ther 1993; 15: 127–36.

Evans SM Funderburk FR Griffiths RR . Zolpidem and triazolam in humans: behavioral and subjective effects and abuse liability. J Pharmacol Exp Ther 1990; 255: 1246–55.

Harvengt C Hulhoven R Desager JP Coupez JM Guillet PH Fuseau E . Drug interactions investigated with zolpidem. In: Sauvanet JP Langer SZ Morselli PL , eds. Imidazopyridines in sleep disorders: a novel experimental and therapeutic approach. New York: Raven Press, 1988: 165–73.

Piergies AA Sweet J Johnson M Roth-Schechter BF Allard S . Pharmacokinetic and pharmacodynamic interaction of zolpidem and fluoxetine (abstract). Presented at the 148th Annual Meeting of the American Psychiatric Association, Miami, FL, May 20–25, 1995: 180.

National prescription audit: basic data report. IMS America, Ltd., January-December 1996.